Complete remission of third recurrence of acute myeloid leukemia after treatment with Imatinib (STI-571)

被引:11
作者
Schittenhelm, M
Aichele, O
Kröber, SM
Brümmendorf, T
Kanz, L
Denzlinger, C [1 ]
机构
[1] Univ Tubingen, Dept Haematol Oncol, Sch Med, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Pathol, D-72076 Tubingen, Germany
关键词
AML; c-kit; CD117; Imatinib; glivec; STI-571;
D O I
10.1080/1042819031000077034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the case of a 76-year old patient with third relapse of AML who was successfully treated with Imatinib. The decision to try Imatinib was guided by bright expression of c-kit on the patient's blasts. Treatment was well tolerated but the dose was reduced for pancytopenia and later stopped completely because of pneumonia. The patient recovered with i.v. antibiotics, antimycotics and s.c. G-CSF. Reevaluation of the bone marrow after the end of treatment demonstrated the absence of malignant blasts. Treatment with Imatinib was started again with the intention to prolong remission duration. During the following months peripheral blood counts stabilized in the normal range indicating that a fourth complete remission has been achieved in this patient. This is the first report demonstrating that Imatinib can induce complete remission in relapsed c-kit positive AML in an elderly patient. Prolonged cytopenia remains a considerable problem indicating that normal haematopoiesis is not completely independent of the signalling cascades inhibited by Imatinib. Nevertheless our report supports further study of this drug in c-kit positive AML.
引用
收藏
页码:1251 / 1253
页数:3
相关论文
共 6 条
[1]  
Denzlinger C, 2000, BRIT J HAEMATOL, V108, P93
[2]   Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor [J].
Heinrich, MC ;
Griffith, DJ ;
Druker, BJ ;
Wait, CL ;
Ott, KA ;
Zigler, AJ .
BLOOD, 2000, 96 (03) :925-932
[3]  
MELONI G, 1994, BLOOD, V84, P2158
[4]   Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance [J].
Radsak, MP ;
Salih, HR ;
Sökler, M ;
Kanz, L ;
Denzlinger, C .
LEUKEMIA, 2002, 16 (09) :1870-1871
[5]   Drug therapy: Imatinib mesylate - A new oral targeted therapy. [J].
Savage, DG ;
Antman, KH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :683-693
[6]   Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse [J].
Sievers, EL ;
Larson, RA ;
Stadtmauer, EA ;
Estey, E ;
Löwenberg, B ;
Dombret, H ;
Karanes, C ;
Theobald, M ;
Bennett, JM ;
Sherman, ML ;
Berger, MS ;
Eten, CB ;
Loken, MR ;
van Dongen, JJM ;
Bernstein, ID ;
Appelbaum, FR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3244-3254